Startup Neurotrope is teaming up with the Icahn School of Medicine at Mount Sinai in New York City to further develop its bryostatins for the treatment of Niemann-Pick disease type C, a rare disease that mostly affects children.
In 2008, the U.S. National Institutes of Health began releasing to the public how much the agency spends in various research categories. I decided to pick out the top-funded disease areas to get a sense of what disorders and diseases the U.S. government is prioritizing.
A new discovery of an ancestral fossil virus buried within everyone's genomes might provide the key to eradicating HIV.
An in vitro technique using samples of beating heart tissue may be able to test the effects of drugs on the heart without unnecessary testing on humans or animals, according to new research.
The U.S. Centers for Disease Control and Prevention reports that the first locally acquired case of chikungunya, a mosquito-borne virus that causes symptoms similar to those of dengue fever, has surfaced in the U.S. in Florida.
Much of Alzheimer's drug research has focused on targeting amyloid beta, a protein long thought to be toxic when it clumps together to form plaques in the brain.
Injecting a gene directly into the heart may be able to replace the need for an electronic pacemaker, according to new research by scientists at the Cedars-Sinai Heart Institute.
A protein found to be essential to the survival of Escherichia coli bacteria may provide a new target for antibiotics, according to researchers from Ohio State University.
Drug development in the Alzheimer's field has been riddled with failures, and many research efforts have focused on pinpointing genetic and environmental factors responsible for causing or accelerating the progression of the disease.
Investigators at the University of Wisconsin-Madison have figured out a way to genetically program stem cells into both red and white cells that make up human blood.
A chemical compound designed by researchers at the University of California, San Francisco, protected mice and rats against degenerative forms of blindness and diabetes by targeting a central stress response area.
Scientists at drug giant Eli Lilly have found that a combination therapy may be more effective at removing clumps of amyloid-β protein--widely thought to contribute to the development of Alzheimer's disease--than the use of one therapy in mice.
Biodefense company Soligenix revealed new data showing that a combination of its vaccines RiVax and VeloThrax induced protective immunity to both ricin toxin and anthrax toxin exposure in an animal study.
Following news that The Scripps Research Institute is in talks to join forces with the University of Southern California, disgruntled faculty members at Scripps are reportedly calling for the removal of President Michael Marletta, saying they have lost confidence in his ability to lead the well-respected center.
Researchers have discovered that, when triggered, certain chemical signals can cause cells to transform into an invasive, liquidy state, giving them the ability to navigate freely through the body. The findings could help drug developers produce new techniques to halt the spread of cancer cells and prevent secondary tumors.
In an effort to more deeply understand the risk factors of schizophrenia, Johns Hopkins researchers have found how a genetic abnormality associated with the mental disorder alters brain cell development.
Researchers have figured out a way to identify stem cells in tissue from deceased human donors and use them to regrow anatomically correct, fully functional human corneas in mice.
A chemical switch that controls the transformation of neural stem cells into neurons and keeps existing nerve cells in the brain alive may be a viable target for neurodegenerative disorders such as Alzheimer's, Parkinson's and autism.
The pact focuses on identifying and selecting novel drug targets with the potential to become potent, selective therapeutics in the areas of oncology, inflammation and diabetes.
An experimental drug that appears to make memories of upsetting events less permanent in mice may help speed the development of treatments for post-traumatic stress disorder.